US2022049320A1PendingUtilityA1

Method for the cytological analysis of cervical cells

75
Assignee: NEODIAGNOSTIX INCPriority: Jul 21, 2008Filed: Oct 31, 2021Published: Feb 17, 2022
Est. expiryJul 21, 2028(~2 yrs left)· nominal 20-yr term from priority
Inventors:Gregory EndressMadhvi UpenderElizabeth LightColyn Cain
C12Q 1/6883C12Q 2600/112C12Q 1/6841A61P 35/00C12Q 2600/118C12Q 1/6886C12Q 2600/156C12N 15/1068C12Q 1/6816
75
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides for a diagnostic test to monitor cancer-specific genetic abnormalities to diagnose cervical cell disorders and predict which patients might progress to cancer. Genetic abnormalities are detected by identification in chromosomal copy number of chromosome 3 and chromosome 5 using FISH analysis of probes targeted to 3q and/or 5p.

Claims

exact text as granted — not AI-modified
1 - 35 . (canceled) 
     
     
         36 . A composition consisting of a plurality of amplification primer pairs, wherein each primer pair individually amplifies a chromosomal location selected from:
 (a) at least one of LRRIQ4, LRRC31, SAMD7, LOC100128164, SEC62, GPR160, PHC3, or PRKCI; and   (b) either CEP3 or CEN7; and   (c) at least one of ADCY2, C5orf49, FASTKD3, MTRR, SEMA5A, SNORD123, TAS2R1, LOC285692, FAM173B, CCT5, CMBL, MARCH6, ROPNIL, DAP, or CTNND2; and   optionally, wherein the chromosomal location further consists of 20q13.   
     
     
         37 . The composition of  claim 36 , wherein (a) is LRRIQ4. 
     
     
         38 . The composition of  claim 36 , wherein (a) is LRRC31. 
     
     
         39 . The composition of  claim 36 , wherein (a) is SAMD7. 
     
     
         40 . The composition of  claim 36 , wherein (a) is LOC100128164. 
     
     
         41 . The composition of  claim 36 , wherein (a) is SEC62. 
     
     
         42 . The composition of  claim 36 , wherein (a) is GPR160. 
     
     
         43 . The composition of  claim 36 , wherein (a) is PHC3. 
     
     
         44 . The composition of  claim 36 , wherein (a) is PRKCI. 
     
     
         45 . The composition of  claim 36 , wherein (a) is at least two of LRRIQ4, LRRC31, SAMD7, LOC100128164, SEC62, GPR160, PHC3, or PRKCI. 
     
     
         46 . The composition of  claim 45 , wherein (a) is GPR160 and PHC3. 
     
     
         47 . The composition of  claim 45 , wherein (a) is at least three of LRRIQ4, LRRC31, SAMD7, LOC100128164, SEC62, GPR160, PHC3, or PRKCI. 
     
     
         48 . The composition of  claim 47 , wherein (a) is GPR160, PHC3, and PRKCI. 
     
     
         49 . The composition of  claim 47 , wherein (a) is SAMD7, LOC100128164, SEC62, GPR160, and PHC3. 
     
     
         50 . The composition of  claim 47 , wherein (a) is LRRIQ4, LRRC31, SAMD7, LOC100128164, SEC62, GPR160 and PHC3. 
     
     
         51 . The composition of  claim 47 , wherein (a) is LRRIQ4, LRRC31, and SAMD7. 
     
     
         52 . The composition of  claim 47 , wherein (a) is LRRIQ4, LRRC31, SAMD7, LOC100128164, and SEC62. 
     
     
         53 . The composition of  claim 36 , wherein (c) is SEMA5A. 
     
     
         54 . The composition of  claim 36 , wherein (c) is CTNND2. 
     
     
         55 . The composition of  claim 36 , wherein (a) is GPR160 and PHC3, (b) is CEN7 and (c) is SEMA5A. 
     
     
         56 . The composition of  claim 36 , wherein (a) is LRRIQ4, LRRC31, and SAMD7, (b) is CEN7 and (c) is SEMA5A. 
     
     
         57 . The composition of  claim 36 , wherein (b) is CEN7 and (c) is CTNND2. 
     
     
         58 . The composition of  claim 36 , wherein (b) is CEN7 and (c) is SNORD123 or TAS2R1. 
     
     
         59 . The composition of  claim 36 , wherein the chromosome location further consists of 20q13. 
     
     
         60 . The composition of  claim 36 , wherein each primer pair is labeled.

Join the waitlist — get patent alerts

Track US2022049320A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.